Companies

Kymera Therapeutics, Inc.

KYMR · CIK 0001815442 · operating

$90.10-1.37%Last updated Mar 2, 11:00 PM

Key Statistics

Valuation

Market Cap$7.21B
P/E
Fwd P/E-22.35
PEG
P/S183.82
P/B4.64
EV/EBITDA-19.45
EV/Rev168.06

Profitability

Gross Margin
Op. Margin-891.07%
Net Margin-794.04%
ROE-19.71%
ROA-17.86%
FCF Margin-597.64%

Financial Health

Current Ratio10.47
Debt/Equity0.10
Free Cash Flow-$234.34M
Div. Yield

Growth & Other

Revenue Growth-16.70%
EPS Growth-23.83%
Beta2.30
52W High$103
52W Low$19.445

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (KYMR) is a biological products, (no diagnostic substances) company incorporated in DE, listed on the Nasdaq. With a market capitalization of $7.2 billion, Kymera Therapeutics, Inc. is a mid-cap company. The stock currently trades at $90.10, down 1.37% today, with a 52-week range of $19.45–$103.00.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$-3.69$-3.69-23.8%
2024$-2.98$-2.98-18.3%
2023$-2.52$-2.52+12.2%
2022$-2.87$-2.87
2021
2020

Annual Reports (10-K) · 6 filings

Report DateFiledAccession Number
2025-12-312026-02-260001193125-26-073395SEC ↗
2024-12-312025-02-270000950170-25-028355SEC ↗
2023-12-312024-02-220000950170-24-018414SEC ↗
2022-12-312023-02-230000950170-23-003935SEC ↗
2021-12-312022-02-240000950170-22-001860SEC ↗
2020-12-312021-03-110001564590-21-012240SEC ↗